Literature DB >> 8911118

The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters.

V Kuenen-Boumeester1, T H Van der Kwast, C C Claassen, M P Look, G S Liem, J G Klijn, S C Henzen-Logmans.   

Abstract

To analyse the clinical significance of the presence of androgen receptors (AR) in breast carcinomas, clinical and histological parameters of 153 primary breast carcinomas (median follow-up 46 months) were examined. Oestrogen (ER) and progesterone receptor (PR) levels were determined in cytosol preparations using enzyme immunoassay assays and in cryostat sections by immunohistochemistry. AR and Ki-67 levels were only determined immunohistochemically. Data were analysed by uni- and multivariate models. 94/153 (61%) breast carcinomas were ER+ PR+ AR+, while 14 cases were only positive for AR. All grade III tumours (n = 17) were steroid receptor negative and 14 (76%) of these cases demonstrated high Ki-67 values suggestive of more aggressive behaviour. Strikingly, 14 ductal carcinomas negative for ER and PR were positive for AR. In univariate analysis, AR as well as ER, tumour size, lymph node status, grade and Ki-67 proved to be significant prognostic factors for disease-free survival (DFS). Multivariate analysis, however, showed lymph node status, tumour size and ER status to be the only independent prognostic factors for DFS within this model. We conclude that simple histological and cell biological parameters, including AR, can be used to select high- and low-risk patients at the time of primary surgery and can provide valuable information on treatment options.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911118     DOI: 10.1016/0959-8049(96)00112-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  49 in total

1.  The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Authors:  Dabei Tang; Shanqi Xu; Qingyuan Zhang; Wenhui Zhao
Journal:  Med Oncol       Date:  2011-04-26       Impact factor: 3.064

2.  Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer.

Authors:  Walter Schippinger; Peter Regitnig; Nadia Dandachi; Klaus-Dieter Wernecke; Thomas Bauernhofer; Hellmut Samonigg; Farid Moinfar
Journal:  Virchows Arch       Date:  2006-04-21       Impact factor: 4.064

3.  Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status.

Authors:  Songmi Noh; Ji-Ye Kim; Ja Seung Koo
Journal:  Tumour Biol       Date:  2014-05-22

Review 4.  Role of the androgen receptor in triple-negative breast cancer.

Authors:  Murtuza Rampurwala; Kari B Wisinski; Ruth O'Regan
Journal:  Clin Adv Hematol Oncol       Date:  2016-03

5.  Development and characterization of new immortalized human breast cell lines

Authors: 
Journal:  Cytotechnology       Date:  1998       Impact factor: 2.058

6.  Androgen resistance in female mice increases susceptibility to DMBA-induced mammary tumors.

Authors:  Ulla Simanainen; Yan Ru Gao; Kirsty A Walters; Geoff Watson; Reena Desai; Mark Jimenez; David J Handelsman
Journal:  Horm Cancer       Date:  2012-06       Impact factor: 3.869

Review 7.  Androgens in human breast carcinoma.

Authors:  Takashi Suzuki; Yasuhiro Miki; Kiyoshi Takagi; Hisashi Hirakawa; Takuya Moriya; Noriaki Ohuchi; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

Review 8.  Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Authors:  Shawna B Matthews; Carol A Sartorius
Journal:  Horm Cancer       Date:  2016-10-28       Impact factor: 3.869

9.  Prolactin/Stat5 and androgen R1881 coactivate carboxypeptidase-D gene in breast cancer cells.

Authors:  Samir Koirala; Lynn N Thomas; Catherine K L Too
Journal:  Mol Endocrinol       Date:  2014-01-16

10.  Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

Authors:  Murtuza Rampurwala; Kari B Wisinski; Mark E Burkard; Sima Ehsani; Ruth M O'Regan; Lakeesha Carmichael; KyungMann Kim; Jill Kolesar; Amye J Tevaarwerk
Journal:  Invest New Drugs       Date:  2016-11-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.